Table 3 Studies that were included in the network meta-analysis
Author | Year | Country | Follow-up period | Design for the study | n | Age (yr.) | BMI (Kg/m2) | Intervention | Control |
|---|---|---|---|---|---|---|---|---|---|
Ganie et al. [3] | 2004 | India | 6 months | Randomized open-labelled clinical trial | 69 | 17.6–28.5 | 20.9–32.1 | Spironolactone (n = 34) | Metformin(n = 35) |
Hoeger et al. [4] | 2008 | USA | 24 weeks | Randomized clinical trial | 43 | 13.7–17.7 | 27.8–46.0 | Metformin (n = 10), COC (n = 11), or lifestyle modification (n = 11) | Placebo (n = 11) |
Sathyapalan et al. [5] | 2009 | UK | 12 weeks | Randomized double-blind clinical trial | 37 | 26.3–29.1 | 31.8–35.4 | Atorvastatin (n = 19) | Placebo (n = 18) |
Kazerooni et al. [1] | 2010 | Iran | 12 weeks | Randomized double-blind clinical trial | 84 | 19.1–30.7 | 27.3–30.3 | Metformin + Simvastatin (n = 42) | Metformin + Placebo (n = 42) |
Romualdi et al. [6]. | 2010 | Italy | 6 months | Randomized double-blind clinical trial | 28 | 20.3–29.8 | 18.4–26.2 | Metformin (n = 15) | Placebo (n = 13) |
Teede et al. [7] | 2010 | Australia | 6 months | Randomized clinical trial | 66 | 26.8–40.2 | 34.3–37.8 | Metformin (n = 36) | COCs (n = 30) |
Raja-Khan et al. [8] | 2011 | USA | 6 weeks | Randomized double-blind clinical trial | 20 | 23.6–38.1 | 25.6–51.9 | Atorvastatin (n = 9) | Placebo (n = 11) |
Banaszewska et al. [2] | 2011 | Poland | 6 months | Randomized open-labelled clinical trial | 97 | 24.7–26.9 | 22.9–25.6 | Simvastatin + Metformin (n = 36) | Simvastatin (n = 28) or Metformin (n = 33) |
Ganie et al. [9] | 2013 | India | 6 months | Randomized open-labelled clinical trial | 169 | 17.2–28.8 | 20.0–30.1 | Spironolactone + Metformin (n = 62) | Spironolactone (n = 51) or Metformin (n = 56) |